Quality Services • CAP & CLIA Accredited
seniors wellness care logo
seniors wellness care name
Genetic Testing & Molecular Diagnostics
Precision Medication • Avoid Adverse Drug EventsPANEL-PGX-18

Pharmacogenomics Drug-Gene Response (PGx)

Pharmacogenomic (PGx) testing unlocks how individual genetic variations impact drug metabolism, efficacy, and adverse reaction risks. By sequencing cytochrome P450 enzymes and drug transporters, providers can replace trial-and-error prescribing with precision pharmacology—optimizing dosages and preventing dangerous drug-drug and drug-gene toxicities.

Medications Profiled250+ Drugs
Enzymes Tested18 Biomarkers
Turnaround Time5–7 Days
Collection MethodBuccal Swab

Check If You Qualify

Takes under 2 minutes • Quick Pre-Qualification

Check Eligibility →
HIPAA 256-Bit Encrypted

Who Should Consider This Screening?

Healthcare providers recommend this diagnostic panel for individuals with the following personal or family health indicators:

Currently taking 3 or more daily prescription medications (Polypharmacy).
History of unexpected side effects, nausea, dizziness, or adverse reactions to medications.
Taking blood thinners (Warfarin, Plavix/Clopidogrel) or cardiovascular therapies.
Suboptimal response to antidepressant, anti-anxiety, or neurological drugs.
Chronic pain management requiring opioid or NSAID dose adjustments.
Starting a new critical prescription regimen where precise therapeutic dosing is vital.

Biomarkers & Genes Evaluated in this Panel

Processed using high-complexity Next-Generation Sequencing (NGS) in CLIA-certified and CAP-accredited partner laboratories.

Gene Symbol / NameClinical SignificanceActionable Impact
CYP2D6Cytochrome P450 Family 2 Subfamily D Member 6Metabolizes ~25% of all common prescription drugs, including beta-blockers, antiarrhythmics, SSRIs, and opioids.Identifies Poor, Intermediate, Normal, or Ultrarapid metabolizers to guide precise dosing and avoid toxicity or therapeutic failure.
CYP2C19Cytochrome P450 Family 2 Subfamily C Member 19Critical for activation of antiplatelet agents (clopidogrel/Plavix), proton pump inhibitors, and antidepressants.Prevents post-stent cardiac complications by identifying clopidogrel resistance and guiding alternative antiplatelet therapies.
CYP2C9 & VKORC1Warfarin & Statin Sensitivity EnzymesRegulates anticoagulant clearance (Coumadin) and statin-induced myopathy risk.Guides initial therapeutic warfarin dosing windows to avoid dangerous hemorrhagic or clotting events.
SLCO1B1Solute Carrier Organic Anion Transporter Family 1B1Controls hepatic uptake of HMG-CoA reductase inhibitors (simvastatin, atorvastatin).Eliminates severe muscle pain (myopathy/rhabdomyolysis) by selecting well-tolerated statin alternatives.

Sample Report & Diagnostic Action Plan

Every patient receives an easy-to-understand diagnostic summary and a detailed clinical report tailored for their primary care doctor.

Sample Result ClassificationModerate Risk Factor
Identified Finding:

CYP2C19 Intermediate Metabolizer (*1/*2) and SLCO1B1 Decreased Function (*5 allele).

Clinician Recommendation:

Consider alternative antiplatelet therapy to clopidogrel (e.g. ticagrelor/Prasugrel) and adjust simvastatin dosage to prevent statin-related myopathy.

Clinical Care & Laboratory Standards

How our licensed physician network and accredited laboratories deliver personalized diagnostic clarity to your doorstep:

100% Physician-Ordered & CLIA Lab Certified

Physician-ordered pharmacogenomic profiling assesses liver enzyme pathways to optimize medication effectiveness and prevent adverse drug interactions across 250+ commonly prescribed medications.

Our network of state-licensed physicians reviews your clinical indications to confirm medical necessity and coordinate care before any kit is mailed.
Physician-Ordered Clinical Screening

Ready to Check Your Eligibility for Pharmacogenomics Drug-Gene Response (PGx)?

Takes under 2 minutes • Painless at-home cheek swab • 100% Physician Reviewed

Start 2-Minute Pre-Qualification →